Literature DB >> 17699208

Heart failure and nephropathy: catastrophic and interrelated complications of diabetes.

Richard E Gilbert1, Kim Connelly, Darren J Kelly, Carol A Pollock, Henry Krum.   

Abstract

Heart failure (HF) is a major contributor to poor quality of life, a leading cause of hospitalization, and cause of premature death. Both kidney disease and diabetes are major and independent risk factors for the development of heart failure, such that individuals with diabetic nephropathy are at especially high risk. Such patients not only are likely to have coronary artery disease and hypertension but also are likely to have diabetic cardiomyopathy, a distinct pathologic entity that is more closely associated with the microvascular than the macrovascular complications of diabetes. In addition to a better understanding of the epidemiology of HF, advances in noninvasive imaging have highlighted the importance of early cardiac dysfunction in diabetes and the high prevalence of HF with preserved left ventricular systolic function. Although significant renal dysfunction is usually an exclusion criterion in HF trials, diabetes is often a prespecified subgroup so that subanalyses of large multicenter clinical trials do provide some guidance in therapeutic decision-making. However, further therapies for both HF and nephropathy in diabetes clearly are needed, and a number of new therapeutic strategies that target both disorders have already entered the clinical arena.

Entities:  

Mesh:

Year:  2005        PMID: 17699208     DOI: 10.2215/CJN.00540705

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  15 in total

1.  The endothelial Dll4-muscular Notch2 axis regulates skeletal muscle mass.

Authors:  Shin Fujimaki; Tomohiro Matsumoto; Masashi Muramatsu; Hiroshi Nagahisa; Naoki Horii; Daiki Seko; Shinya Masuda; Xuerui Wang; Yoko Asakura; Yukie Takahashi; Yuta Miyamoto; Shingo Usuki; Kei-Ichiro Yasunaga; Yasutomi Kamei; Ryuichi Nishinakamura; Takashi Minami; Takaichi Fukuda; Atsushi Asakura; Yusuke Ono
Journal:  Nat Metab       Date:  2022-02-28

Review 2.  Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.

Authors:  Peter Rossing
Journal:  Kidney Int Suppl (2011)       Date:  2022-03-18

3.  Cardiac and renal function are progressively impaired with aging in Zucker diabetic fatty type II diabetic rats.

Authors:  John Baynes; David B Murray
Journal:  Oxid Med Cell Longev       Date:  2009 Nov-Dec       Impact factor: 6.543

4.  Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.

Authors:  Thomas E Delea; Oleg Sofrygin; James L Palmer; Helen Lau; Veronica C Munk; Jennifer Sung; Alan Charney; Hans-Henrik Parving; Sean D Sullivan
Journal:  J Am Soc Nephrol       Date:  2009-09-17       Impact factor: 10.121

5.  Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 diabetes and without known heart disease: the Thousand & 1 Study.

Authors:  Magnus T Jensen; Peter Sogaard; Ida Gustafsson; Jan Bech; Thomas F Hansen; Thomas Almdal; Simone Theilade; Tor Biering-Sørensen; Peter G Jørgensen; Søren Galatius; Henrik U Andersen; Peter Rossing
Journal:  Diabetologia       Date:  2019-10-30       Impact factor: 10.122

6.  3',4'-Dihydroxyflavonol antioxidant attenuates diastolic dysfunction and cardiac remodeling in streptozotocin-induced diabetic m(Ren2)27 rats.

Authors:  Fay Lin Khong; Yuan Zhang; Amanda J Edgley; Weier Qi; Kim A Connelly; Owen L Woodman; Henry Krum; Darren J Kelly
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240

7.  Chinese medicines in the treatment of experimental diabetic nephropathy.

Authors:  Jing-Yi Liu; Xiao-Xin Chen; Sydney Chi-Wai Tang; Stephen Cho-Wing Sze; Yi-Bin Feng; Kai-Fai Lee; Kalin Yan-Bo Zhang
Journal:  Chin Med       Date:  2016-02-24       Impact factor: 5.455

8.  Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus.

Authors:  Jung-Chi Hsu; Chih-Yuan Wang; Mao-Yuan M Su; Lian-Yu Lin; Wei-Shiung Yang
Journal:  Sci Rep       Date:  2019-10-25       Impact factor: 4.379

9.  Defining the Progression of Diabetic Cardiomyopathy in a Mouse Model of Type 1 Diabetes.

Authors:  Miles J De Blasio; Nguyen Huynh; Minh Deo; Leslie E Dubrana; Jesse Walsh; Andrew Willis; Darnel Prakoso; Helen Kiriazis; Daniel G Donner; John C Chatham; Rebecca H Ritchie
Journal:  Front Physiol       Date:  2020-02-20       Impact factor: 4.566

Review 10.  Many Cells Make Life Work-Multicellularity in Stem Cell-Based Cardiac Disease Modelling.

Authors:  Brian X Wang; Worrapong Kit-Anan; Cesare M N Terracciano
Journal:  Int J Mol Sci       Date:  2018-10-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.